Evidence map›Paper›PMID 19410646›Full record

ArticleCellular signalling2009

Novel phosphotyrosine targets of FGFR2IIIb signaling.

Yongde Luo, Chaofeng Yang, Chengliu Jin, Rui Xie, Fen Wang, Wallace L McKeehan

Abstract read
In one paragraph

Article in Cellular signalling, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Fibroblast growth factors, old kids on the new block.Seminars in cell & developmental biology · 2016
    Review
  13. Article
  14. Review
  15. Proliferation and migration of hepatoblastoma cells are mediated by IRS-4 via PI3K/Akt pathways.International journal of clinical and experimental medicine · 2014
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yongde LuoIBT Proteomics and Nanotechnology Laboratory, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas 77030-3303, USA.
Chaofeng Yang
Chengliu Jin
Rui Xie
Fen Wang
Wallace L McKeehan
Texas A&M Health Science Center · USTexas A&M University · US

Funding

GROWTH FACTORS IN PROSTATE CANCERR01CA059971 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI MCKEEHAN, WALLACE LEE · 1993 to 2007
$2.4M
HUMAN HEPATOCYTE GROWTH FACTORSR01DK035310 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI MCKEEHAN, WALLACE LEE · 1986 to 2006
$1.9M
Mechanism of action of STAMP - a new comodulator of glucocorticoid receptorsZ01DK047039 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SIMONS, S STONEY · 2007 to 2008
$536k
Intramural NIH HHS Z01 DK047039NCI NIH HHS CA059971NCI NIH HHS R01 CA059971NIDDK NIH HHS R01 DK035310
6 · The paper itself

Abstract

In partnership exclusively with the epithelial FGFR2IIIb isotype and a structurally-specific heparan sulfate motif, stromal-derived FGF7 delivers both growth-promoting and growth-limiting differentiation signals to epithelial cells that promote cellular homeostasis between stromal and epithelial compartments. Intercompartmental homeostasis supported by FGF7/FGFR2IIIb is subverted in many solid epithelial tumors. The normally mesenchymal-derived homologue FGFR1 drives proliferation and a progressive tumor-associated phenotype when it appears ectopically in epithelial cells. In order to understand the mechanism underlying the unique biological effects of FGFR2IIIb, we developed an inducible FGFR2IIIb expression system that is specifically dependent on FGF7 for activation in an initially unresponsive cell line to avoid selection for only the growth-promoting aspects of FGFR2IIIb signaling. We then determined FGF7/FGFR2IIIb signaling-specific tyrosine phosphorylated proteins within 5 min after FGF7 stimulation by phosphopeptide immunoaffinity purification and nano-LC-MS/MS. The FGF7/FGFR2 pair caused tyrosine phosphorylation of multiple proteins that have been implicated in the growth stimulating activities of FGFR1 that included multi-substrate organizers FRS2alpha and IRS4, ERK2 and phosphatases SHP2 and SHIP2. It uniquely phosphorylated CDK2 and phosphatase PTPN18 on sites involved in the attenuation of cell proliferation, and several factors that maintain nuclear-cytosolic relationships (emerin and LAP2), protein structure and other cellular fine structures as well as some proteins of unknown functions. Several of the FGF7/FGFR2IIIb-specific targets have been associated with maintenance of function and tumor suppression and disruption in tumors. In contrast, a number of pTyr substrates associated with FGF2/FGFR1 that are generally associated with intracellular Ca(2+)-phospholipid signaling, membrane and cytoskeletal plasticity, cell adhesion, migration and the tumorigenic phenotype were not observed with FGF7/FGFR2IIIb. Our findings provide specific downstream targets for dissection of causal relationships underlying the distinct role of FGF7/FGFR2IIIb signaling in epithelial cell homeostasis.

Indexed as

Signal TransductionAmino Acid SequenceAnimalsCell LineFibroblast Growth Factor 7HumansMolecular Sequence DataPhosphopeptidesPhosphorylationPhosphotyrosineProtein Tyrosine PhosphatasesRatsReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 2FGF7 protein, humanFibroblast Growth Factor 7keratinocyte growth factor receptorPhosphopeptidesPhosphotyrosineProtein Tyrosine PhosphatasesReceptor, Fibroblast Growth Factor, Type 1Receptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID19410646
PMCPMC2782441
OpenAlexW2139419157

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.